Adult occult autoimmune diabetes
Conditions
Interventions
Experimental group:Insulin+Chiglitazar48mg
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of diabetes mellitus (WHO1999 standard); 2. Age 25-75 years old; 3. Not dependent on insulin therapy within 6 months after diagnosis of diabetes; 4. Duration =0.3nmol/L; 7.BMI>=25 Kg/m2, < 35 Kg/m2; 8. Voluntarily sign informed consent and agree to enter the trial group.
Exclusion criteria
Exclusion criteria: 1. Chronic or acute infection within 4 weeks prior to visit 2. Fasting blood glucose (FPG) > 13.3 mmol/L (240 mg/dL); 3. Triglyceride (TG) > 500 mg /dL (5.65 mmol/L); 4. Total cholesterol (TC) >250mg/dl (>6.45mmol/L); 5. Refractory hypertension [that is, on the basis of improving the lifestyle, the blood pressure is still not up to standard after 1 month of applying a reasonably tolerable amount of 3 or more antihypertensive drugs (including diuretics), or the blood pressure can be effectively controlled by taking 4 or more antihypertensive drugs]; 6. History of any malignant tumors 7. A clear diagnosis of severe osteoporosis or any other known bone disease; 8. History of acute complications of diabetes such as diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome and lactic acidosis; 9. Severe microvascular complications (proliferative retinopathy; Urinary albumin/creatinine ratio >300 mg/g; Marked peripheral neuropathy, etc.); 10. The New York Heart Association (NYHA) defines congestive heart failure as grade III or IV 11. Significant liver and kidney dysfunction and systemic disease (significant liver dysfunction is defined as AST>2.5 times the upper limit of normal and/or ALT>2.5 times the upper limit of normal and/or total bilirubin >1.5 times the upper limit of normal; Renal dysfunction was defined as moderate to severe renal insufficiency (eGFR<60 ml/ (min*1.73m2)). 12. Pregnant or lactating women, women of childbearing age who are unable or unwilling to use adequate contraception; Participating in a clinical trial of another drug or medical device in or within 3 months prior to screening; 13. The investigator considers it inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of ?C peptide (?CP= 2hCP-FCP) from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in fasting C-peptide and C-peptide (2hCP) at 2 hours postprandial from baseline;Changes in insulin dosage from baseline;Changes in lipid indexes (TG, TC, LDL-C, HDL-C) from baseline;Changes in proinsulin and glucagon from baseline;Changes in HOMA2-ß from baseline; | — |
Countries
China
Contacts
Public ContactMing Liu/Zheng Fangqiu
Tianjin Medical University General Hospital
Outcome results
None listed